Peptide-Based Approaches to Celiac Disease
Celiac Disease and Peptides
3 distinct strategies
Peptide therapies for celiac disease target three separate mechanisms: immune tolerance, tight junction regulation, and gluten peptide degradation.
Multiple clinical trials, 2017-2026
Multiple clinical trials, 2017-2026
View as imageCeliac disease has no approved drug treatment. The only option is a lifelong gluten-free diet, which is difficult to maintain perfectly and fails to resolve symptoms in up to 30% of patients who follow it strictly. The disease is driven by an immune reaction to specific gluten-derived peptide fragments, making it one of the few autoimmune conditions where the triggering antigen is known. That clarity has enabled peptide-based therapeutic strategies that would be impossible in most autoimmune diseases. Three fundamentally different approaches are being tested: teaching the immune system to tolerate gluten peptides, sealing the intestinal barrier so gluten fragments cannot reach immune cells, and degrading gluten peptides before they trigger a response. For context on how gluten peptides cause the disease in the first place, see our article on how gluten-derived peptides trigger celiac. For the leading tight junction approach, see our pillar article on larazotide acetate.
Key Takeaways
- Nexvax2, a three-peptide vaccine targeting HLA-DQ2.5-restricted T cell epitopes, was safe but failed to protect against gluten-induced symptoms in a Phase 2 trial of approximately 150 patients (Truitt et al., Alimentary Pharmacology and Therapeutics, 2019)
- KAN-101, a liver-targeted gliadin peptide conjugate, showed dose-dependent modulation of gluten-induced IL-2 and reduction in gliadin-specific T cells in a Phase 1 trial with no dose-limiting toxicities (Lancet Gastroenterology and Hepatology, 2023)
- Larazotide acetate, an eight-amino-acid peptide that tightens intestinal junctions, reached Phase 3 but was discontinued in 2022 after interim analysis showed insufficient separation from placebo (Slifer et al., AJP-GI, 2021)
- Fecal beta-defensin-2 was 56% higher in pediatric celiac patients (99.6 vs 64.0 ng/mL), indicating altered antimicrobial peptide responses in celiac gut mucosa (Kamilova et al., Frontiers in Pediatrics, 2022)
- The 33-mer gliadin peptide, resistant to all human digestive enzymes, contains six overlapping T cell epitopes and is the primary immunogenic fragment driving celiac disease (Qiao et al., Journal of Immunology, 2004)
- EQ302, an orally delivered stapled peptide inhibiting both IL-15 and IL-21, targets two cytokines that synergistically drive T and B cell aggression in celiac disease and is entering Phase 1 trials
Why Celiac Disease Is Uniquely Suited to Peptide Therapy
Most autoimmune diseases have unknown triggers. Celiac disease does not. The immune response is directed against specific peptide fragments produced when gluten proteins are digested. The most immunogenic of these is the 33-mer gliadin peptide, a 33-amino-acid fragment that resists degradation by every human digestive protease. This fragment contains six overlapping T cell epitopes that bind HLA-DQ2.5, the genetic marker carried by approximately 95% of celiac patients.[1]
The enzyme tissue transglutaminase (tTG) deamidates specific glutamine residues in these peptides, converting them to glutamic acid. This modification dramatically increases their binding affinity for HLA-DQ2.5 molecules on antigen-presenting cells. The resulting peptide-HLA complex activates CD4+ T cells, initiating the inflammatory cascade that destroys intestinal villi. Because the antigen (gluten peptides), the genetic risk factor (HLA-DQ2/DQ8), and the modifying enzyme (tTG) are all known, celiac disease offers more precise therapeutic targets than virtually any other autoimmune condition.
This molecular clarity has enabled three peptide-based strategies: tolerance-inducing peptide therapies that attempt to shut down the gluten-specific T cell response, tight junction modulators that prevent gluten fragments from reaching immune cells, and enzymatic approaches that destroy immunogenic peptides before they can be presented.
Nexvax2: The Peptide Vaccine That Failed
Nexvax2 was the most ambitious attempt at peptide immunotherapy for celiac disease. Developed by ImmusanT, it consisted of three synthetic peptides containing six HLA-DQ2.5-restricted immunodominant T cell epitopes from gliadin and glutenin. The concept was desensitization: by injecting these peptides subcutaneously at escalating doses, the therapy aimed to induce T cell tolerance to gluten.
The Phase 1 trial, a randomized, double-blind, placebo-controlled study, established safety and characterized the immune response. Escalating dose regimens were tested in celiac patients, and the peptide triggered measurable cytokine responses, confirming that it engaged the relevant T cells. No serious safety concerns emerged, though injection-site reactions were common.[2]
A subsequent randomized study tested both subcutaneous and intradermal delivery routes. Both were tolerable, and the study demonstrated that Nexvax2 could modulate immune markers at certain doses.[3]
The Phase 2 trial (RESET CeD) was the definitive test. Approximately 150 patients across 41 sites in the US, Australia, and New Zealand were randomized to Nexvax2 or placebo, then challenged with bolus gluten exposure. An interim analysis led to early termination: Nexvax2 did not reduce gluten-induced symptoms compared to placebo. The vaccine was safe, but it simply did not work.
The failure carries lessons. Celiac disease involves dozens of immunogenic gluten peptides, not just six. The three Nexvax2 peptides may have been insufficient to cover the full antigenic landscape. Additionally, subcutaneous injection of immunogenic peptides can activate T cells rather than tolerize them, depending on the dose, timing, and co-stimulatory context. The Nexvax2 program ended in 2019, and ImmusanT was subsequently acquired.
KAN-101: Liver-Targeted Immune Tolerance
KAN-101 represents a mechanistically distinct approach to the same goal. Rather than injecting gluten peptides subcutaneously and hoping for tolerance, KAN-101 conjugates a deamidated alpha-gliadin peptide to a liver-targeting glycosylation signature. The rationale exploits a known immunological principle: the liver is naturally tolerogenic. Antigens processed by liver sinusoidal endothelial cells and Kupffer cells tend to induce tolerance rather than immunity. By routing gluten peptides through hepatic antigen presentation, KAN-101 aims to reprogram the immune response.
The Phase 1 trial (ACeD), published in The Lancet Gastroenterology and Hepatology in 2023, enrolled adults with biopsy-confirmed, HLA-DQ2.5-positive celiac disease. Single ascending doses (0.15 to 1.5 mg/kg intravenous) were tested in an open-label design, followed by a randomized, placebo-controlled multiple ascending dose phase. KAN-101 showed rapid systemic clearance (approximately six hours) with no accumulation after repeated dosing. No dose-limiting toxicities were observed and no maximum tolerated dose was reached.
The immunological data were more encouraging than Nexvax2's. KAN-101 produced dose-dependent modulation of gluten-induced IL-2, a cytokine directly produced by activated gluten-specific T cells. Higher doses tempered the T cell response to subsequent gluten challenge and reduced gliadin-specific T cell numbers. The compound also favorably impacted gut-homing CD8+ T cells.
KAN-101 received FDA Fast Track designation. Phase 2 development is underway. The key question is whether hepatic tolerance induction can suppress a mucosal immune response strongly enough to allow gluten consumption. The Phase 1 data showed immune modulation, not complete tolerance. Whether the observed reductions in IL-2 and gliadin-specific T cells translate to clinical protection from gluten-induced villous atrophy remains to be demonstrated.
Larazotide Acetate: Sealing the Barrier
Larazotide acetate takes an entirely different approach. Rather than modifying the immune response, this eight-amino-acid synthetic peptide tightens the intestinal tight junctions that control paracellular permeability. In celiac disease, gliadin fragments trigger zonulin release, which opens tight junctions and allows immunogenic peptides to cross the epithelial barrier and reach lamina propria immune cells. Larazotide blocks this process.[4]
The drug showed promise in Phase 2. A randomized controlled trial demonstrated that larazotide reduced symptoms in celiac patients who remained symptomatic despite following a gluten-free diet. The peptide was well tolerated and produced a statistically significant improvement in symptom scores at the 0.5 mg dose.
The Phase 3 trial (CedLara), sponsored by 9 Meters Biopharma, enrolled patients with persistent celiac symptoms on a gluten-free diet. An interim analysis in 2022 found that the treatment effect was too small to reach statistical significance even with a substantially expanded enrollment. The trial was discontinued.
The Phase 3 failure does not necessarily invalidate the mechanism. Several factors may have contributed: the patient population (symptomatic despite diet adherence) is heterogeneous, and symptom endpoints are notoriously variable in celiac trials. The Phase 2 signal was modest, and it may have been inflated by the smaller trial size. Whether larazotide could work as an adjunct to dietary therapy during intentional or accidental gluten exposure, rather than as a standalone symptom treatment, remains an open question.
For more on how tight junction modulation relates to intestinal permeability broadly, see BPC-157 and leaky gut.
EQ302: A Stapled Peptide Targeting IL-15 and IL-21
EQ302 represents the newest peptide approach to celiac disease. Developed by Equillium, it is a first-in-class orally delivered stapled peptide that simultaneously inhibits IL-15 and IL-21, two cytokines that synergistically drive T and B cell activation in celiac disease.
IL-15 is overexpressed in the celiac intestinal epithelium and drives the expansion of cytotoxic intraepithelial lymphocytes that directly kill enterocytes. IL-21, produced by activated CD4+ T cells, amplifies B cell responses and promotes the production of anti-tTG and anti-gliadin antibodies. Blocking both simultaneously targets the disease at two levels: the innate-like epithelial destruction and the adaptive immune amplification.
The stapled peptide design addresses a practical challenge. Hydrocarbon staples lock the peptide into a helical conformation, conferring stability against gastrointestinal proteases while retaining cytokine inhibitory activity. In preclinical studies, oral EQ302 inhibited IL-15-induced interferon-gamma transcription locally in the gastrointestinal tract of mice, suggesting the peptide can act at the disease site without requiring systemic absorption.
EQ302 evolved from EQ102, its parent peptide, which demonstrated pharmacodynamic activity but had lower-than-expected oral bioavailability. A first-in-human Phase 1 trial was targeted for the second half of 2025. No human safety or efficacy data are available yet.
Gluten-Degrading Enzymes: Destroying the Trigger
While not peptide therapeutics themselves, prolyl endopeptidases are enzymes that degrade the specific proline-rich peptide sequences in gluten that make it resistant to human digestion. The 33-mer gliadin peptide survives gastric, pancreatic, and brush border digestion because human proteases cannot efficiently cleave peptide bonds adjacent to proline residues. Microbial prolyl endopeptidases fill this gap.
AN-PEP (Aspergillus niger prolyl endopeptidase) operates at stomach pH (4-5), resists pepsin degradation, and is approximately 60 times more efficient at cleaving gluten peptides than other prolyl oligopeptidases. In a gastrointestinal model, AN-PEP degraded gluten so efficiently in the stomach compartment that minimal immunogenic peptide reached the duodenum.
Latiglutenase (ALV003) combines two engineered proteases: a modified prolyl oligopeptidase from Sphingomonas capsulata and a cysteine protease from barley (EP-B2). This combination cleaves gluten peptides at both proline and glutamine residues. In a clinical trial, latiglutenase significantly reduced mucosal damage when administered with 2 grams of gluten daily for six weeks.
The enzyme approach is complementary to peptide immunotherapy. Even if tolerance-inducing peptides like KAN-101 succeed, patients would still benefit from enzymatic degradation of gluten during accidental exposures. The strategies are not mutually exclusive.
Antimicrobial Peptide Disruption in Celiac Disease
The celiac gut shows altered antimicrobial peptide expression, which may contribute to the disease process beyond the primary gluten-driven immune response. In a study of pediatric celiac patients, fecal beta-defensin-2 levels were significantly elevated compared to healthy controls (99.6 vs 64.0 ng/mL, p < 0.001).[5]
Beta-defensin-2 is an inducible antimicrobial peptide produced by intestinal epithelial cells in response to inflammation and microbial stimulation. Its elevation in celiac disease reflects the chronic inflammatory state of the gut mucosa and the dysbiotic microbiome that accompanies villous atrophy. Whether antimicrobial peptide dysregulation contributes to disease perpetuation or simply reflects it is not yet established, but it offers a potential biomarker for monitoring mucosal healing during treatment.
The Evolutionary Paradox of Celiac-Triggering Peptides
The 33-mer gliadin peptide is not a random sequence. Ozuna and colleagues traced its evolution across wheat species, finding that the six overlapping T cell epitopes within the 33-mer arose through gene duplication events in the alpha-gliadin gene family during wheat domestication. Hexaploid bread wheat (Triticum aestivum) accumulated the highest density of celiac-triggering epitopes, while some diploid wild wheat relatives carry significantly fewer.[6]
This finding has implications for peptide therapy design. If different wheat species produce different immunogenic peptide profiles, then the choice of peptide epitopes included in a tolerizing vaccine matters. Nexvax2 targeted six epitopes; the actual antigenic landscape in a modern bread wheat-based diet may be substantially broader. Future peptide vaccines may need to account for the full diversity of celiac epitopes that a patient's diet generates.
Where Peptide Celiac Therapies Stand
The track record is sobering. The two peptide-based therapies that advanced furthest in clinical trials, Nexvax2 and larazotide, both failed to meet their primary endpoints. KAN-101's liver-targeting approach is the most scientifically innovative remaining candidate, but it has only completed Phase 1 with 36 patients.
The pattern across all three programs reveals a consistent challenge: modulating the celiac immune response enough to allow normal gluten consumption is far harder than anticipated. Nexvax2 could not cover enough epitopes. Larazotide could not seal the barrier completely enough. The disease may require combination approaches, perhaps liver-targeted tolerance plus enzymatic gluten degradation plus tight junction reinforcement, rather than any single peptide strategy.
EQ302's dual cytokine blockade introduces a genuinely novel mechanism, but it has not yet been tested in humans. The next two years of clinical data from KAN-101 Phase 2 and EQ302 Phase 1 will determine whether peptide therapeutics can advance beyond the failures that have defined the field so far.
The Bottom Line
Peptide-based celiac disease therapies target three mechanisms: immune tolerance induction, tight junction sealing, and gluten peptide degradation. Nexvax2 (peptide vaccine) and larazotide acetate (tight junction peptide) both failed in advanced clinical trials. KAN-101, which routes a gliadin peptide through the liver's tolerogenic pathways, showed dose-dependent immune modulation in Phase 1 and is now the leading peptide candidate. EQ302, a stapled peptide blocking IL-15 and IL-21, is entering human testing. The field's repeated failures suggest that single-mechanism approaches may be insufficient and that combination strategies will be necessary.